JAZZ241220C90000
- 38.18
- 0.000.00%
Jazz Pharmaceuticals Newsroom
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Analyst Ratings
TD Cowen Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $163
UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Raises Target Price to $128
Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $162
Jazz Pharmaceuticals Analyst Ratings
J.P. Morgan Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Barclays Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $190
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Radnet (RDNT) and Eli Lilly & Co (LLY)
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $207
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $130 to $230
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Privia Health Group (PRVA) and Jazz Pharmaceuticals (JAZZ)
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $140 to $207
Jazz Pharmaceuticals Analyst Ratings
RBC Capital Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Robust Q3 2024 Performance and Optimistic Outlook Reinforce Buy Rating for Jazz Pharmaceuticals
Hold Rating for Jazz Pharmaceuticals Amid Oncology Revenue Challenges and Strategic Product Launches